Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be classified into three types on the basis of cause: acquired ataxia, genetic ataxia, and idiopathic ataxia. Acquired ataxia is caused by external factors such as vitamin deficiencies, head trauma, microbial infection, brain tumor, and exposure to drugs or alcohol. Genetic ataxia is caused when a damaged gene which leads to ataxia is passed from one generation to the other. Idiopathic ataxia is a condition wherein the cause is unknown. Few of the symptoms associated with ataxia include decreasing coordination, trouble in walking, impaired balance with frequent falls, loss of fine motor skills, muscle tremors, slurred speech, vision problems, and others. Ataxia can develop at any age and is progressive in nature i.e. it worsens with time.
Market Dynamics
The increasing incidence of ataxia, rising research and development activities for the development of novel therapeutics for the treatment of ataxia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global ataxia market over the forecast period.
For instance, according to an article published by the Clinical and Translational Neuroscience journal, in August 2018, it is estimated that the global occurrence rate of ataxia is 26/100,000 in children wherein the occurrence rate for dominant hereditary cerebellar ataxia is 2.7/100,000 and the occurrence rate for recessive hereditary cerebellar ataxia 3.3/100,000, as of 2018.
Key features of the study:
- This report provides in-depth analysis of the global ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ataxia market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ataxia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ataxia market
Detailed Segmentation:
- Global Ataxia Market, By Treatment Type:
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- Global Ataxia Market, By Disease Type:
- Friedreich's Ataxia
- Ataxia-telangiectasia
- Spinocerebellar Ataxias
- Episodic Ataxia
- Others (Multiple System Atrophy (MSA))
- Global Ataxia Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Ataxia Market, By Region:
- North America
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- CRISPR Therapeutics
- Acorda Therapeutics
- Capsida Biotherapeutics Inc.
- Larimar Therapeutics, Inc.
- Healx
- Intellia Therapeutics, Inc.
- Editas Medicine
- bluebird bio, Inc.
- Sanofi
- Merck & Co., Inc.
- H. Lundbeck A/S
- Cellectis SA
- Bio-Techne
- GlaxoSmithKline plc
- Allergan
“*” marked represents similar segmentation in other categories in the respective section.
